Brooklyn ImmunoTherapeutics Inc
BTX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$985.03M
Close$
$0.45
94.7% downside
Current Fair Value
94.7% downsideOvervalued by 94.7% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $985.03 Million |
|---|---|
| Enterprise Value | $984.59 Million |
| Annual dividend | $0.63 |
| Dividend yield | 7.46% |
| Earnings per Share | $0 |
| Beta | 1.39 |
| Outstanding Shares | - |
Return
| Return on Equity | -4.91% |
|---|---|
| Return on Assets | -4.79% |
| Return on Invested Capital | -2.02% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 1646.46 |
| Enterprise Value to EBIT | -52.53 |
| Enterprise Value to Net Income | -22 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Brooklyn ImmunoTherapeutics Inc
2,018 employees
Brooklyn is focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. The company is also exploring opportunities to a...